|
End-of-day quote
Shenzhen S.E.
2026-09-04
|
5-day change | 1st Jan Change | ||
| 11.11 CNY | +1.00% |
|
+0.09% | -8.56% |
| 08-20 | Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 05-22 | Zhuhai Rundu Pharmaceutical Wins China Approval for Pain Relief Drug | MT |
| Fiscal Period: December | 2016 (CNY) | 2017 (CNY) | 2018 (CNY) | 2019 (CNY) | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.19B | 1.36B | 1.28B | 1.18B | 1.16B | |||||
Other Revenues, Total | 1.98M | 9.01M | 10.06M | 5.53M | 18.08M | |||||
Total Revenues | 1.19B | 1.37B | 1.29B | 1.18B | 1.18B | |||||
Cost of Goods Sold, Total | 479M | 636M | 685M | 692M | 765M | |||||
Gross Profit | 711M | 736M | 607M | 490M | 412M | |||||
Selling General & Admin Expenses, Total | 476M | 460M | 393M | 310M | 332M | |||||
Provision for Bad Debts | 487K | 2.56M | -728K | 139K | 1.17M | |||||
R&D Expenses | 84.27M | 92.34M | 127M | 129M | 92.38M | |||||
Other Operating Expenses | 12M | 15.25M | 15.46M | 11.27M | 12.62M | |||||
Other Operating Expenses, Total | 573M | 570M | 535M | 451M | 438M | |||||
Operating Income | 138M | 166M | 72.31M | 39.52M | -26.57M | |||||
Interest Expense, Total | -1.77M | -6.97M | -16.12M | -15.78M | -13.11M | |||||
Interest And Investment Income | 2.33M | 1.48M | 2.25M | 1.33M | 1.67M | |||||
Net Interest Expenses | 559K | -5.49M | -13.86M | -14.45M | -11.44M | |||||
Currency Exchange Gains (Loss) | -1.34M | 1.3M | 1.76M | 2.85M | -379K | |||||
Other Non Operating Income (Expenses) | -860K | -453K | -1.12M | -1.94M | -5.08M | |||||
EBT, Excl. Unusual Items | 137M | 161M | 59.09M | 25.98M | -43.46M | |||||
Restructuring Charges | - | - | - | - | -13.32M | |||||
Gain (Loss) On Sale Of Investments | -18.02K | -24.99K | -364K | 13.48K | -12.07K | |||||
Gain (Loss) On Sale Of Assets | - | 46.8K | 152K | 18.02M | 628K | |||||
Asset Writedown | -228K | -326K | -148K | -433K | -16.78M | |||||
Insurance Settlements | - | - | - | - | - | |||||
Other Unusual Items | 15.14M | 19.86M | 27.31M | -955K | 13.36M | |||||
EBT, Incl. Unusual Items | 152M | 181M | 86.04M | 42.63M | -59.59M | |||||
Income Tax Expense | 11.97M | 25.46M | 19.14M | 2.74M | 3.88M | |||||
Earnings From Continuing Operations | 140M | 155M | 66.9M | 39.88M | -63.47M | |||||
Net Income to Company | 140M | 155M | 66.9M | 39.88M | -63.47M | |||||
Net Income - (IS) | 140M | 155M | 66.9M | 39.88M | -63.47M | |||||
Net Income to Common Incl Extra Items | 140M | 155M | 66.9M | 39.88M | -63.47M | |||||
Net Income to Common Excl. Extra Items | 140M | 155M | 66.9M | 39.88M | -63.47M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.42 | 0.46 | 0.2 | 0.12 | -0.19 | |||||
Basic EPS - Continuing Operations | 0.42 | 0.46 | 0.2 | 0.12 | -0.19 | |||||
Basic Weighted Average Shares Outstanding | 335M | 335M | 334M | 332M | 334M | |||||
Net EPS - Diluted | 0.42 | 0.46 | 0.2 | 0.12 | -0.19 | |||||
Diluted EPS - Continuing Operations | 0.42 | 0.46 | 0.2 | 0.12 | -0.19 | |||||
Diluted Weighted Average Shares Outstanding | 335M | 335M | 334M | 332M | 334M | |||||
Normalized Basic EPS | 0.26 | 0.3 | 0.11 | 0.05 | -0.08 | |||||
Normalized Diluted EPS | 0.26 | 0.3 | 0.11 | 0.05 | -0.08 | |||||
Dividend Per Share | 0.22 | 0.25 | 0.2 | 0.15 | - | |||||
Payout Ratio | 59.13 | 57.68 | 153.04 | 212.36 | -100.97 | |||||
Supplemental Items | ||||||||||
EBITDA | 198M | 235M | 183M | 173M | 115M | |||||
EBITA | 140M | 168M | 73.88M | 41.15M | -25.14M | |||||
EBIT | 138M | 166M | 72.31M | 39.52M | -26.57M | |||||
EBITDAR | 200M | 237M | 188M | 178M | 117M | |||||
Total Revenues (As Reported) | 1.19B | 1.37B | 1.29B | 1.18B | 1.18B | |||||
Effective Tax Rate - (Ratio) | 7.89 | 14.07 | 22.25 | 6.44 | -6.52 | |||||
Current Domestic Taxes | 8.94M | 27.08M | 17.28M | 3M | 8.45M | |||||
Total Current Taxes | 8.94M | 27.08M | 17.28M | 3M | 8.45M | |||||
Deferred Domestic Taxes | 3.03M | -1.62M | 1.87M | -260K | -4.57M | |||||
Total Deferred Taxes | 3.03M | -1.62M | 1.87M | -260K | -4.57M | |||||
Normalized Net Income | 85.53M | 101M | 36.93M | 16.24M | -27.16M | |||||
Interest Capitalized | 6.14M | 9.5M | - | 3.06M | 2.04M | |||||
Interest on Long-Term Debt | - | - | 159K | 383K | 671K | |||||
Non-Cash Pension Expense | - | - | 357K | 1.88M | 13.32M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | - | 334M | 255M | 193M | 202M | |||||
Selling and Marketing Expenses | 417M | 390M | 315M | 246M | 260M | |||||
General and Administrative Expenses | 59.19M | 70.19M | 77.88M | 64.5M | 71.7M | |||||
Research And Development Expense From Footnotes | 92.14M | 95.59M | 129M | 131M | 94.12M | |||||
Net Rental Expense, Total | 1.54M | 1.56M | 4.55M | 4.56M | 2.52M | |||||
Imputed Operating Lease Interest Expense | 548K | 545K | 1.13M | 1.28M | 591K | |||||
Imputed Operating Lease Depreciation | 994K | 1.02M | 3.42M | 3.28M | 1.93M | |||||
Maintenance & Repair Expenses, Total | 16.15M | 5.65M | 3.4M | 4.76M | 2.7M | |||||
Stock-Based Comp., G&A Exp. (Total) | -6.7M | - | - | - | - | |||||
Total Stock-Based Compensation | -6.7M | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
















